Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 3823121, 7 pages
http://dx.doi.org/10.1155/2016/3823121
Research Article

Comparison of Serum MicroRNA21 and Tumor Markers in Diagnosis of Early Non-Small Cell Lung Cancer

Department of Clinical Laboratory, Affiliated Yancheng Hospital, School of Medicine, Southeast University, Yancheng, Jiangsu 224001, China

Received 3 October 2015; Revised 12 December 2015; Accepted 15 December 2015

Academic Editor: Stamatios Theocharis

Copyright © 2016 Mingzhong Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Yamanashi, S. Marumo, K. Miura, and M. Kawashima, “Long-term survival in a case of pleomorphic carcinoma with a brain metastasis,” Case Reports in Oncology, vol. 7, no. 3, pp. 799–803, 2014. View at Publisher · View at Google Scholar
  2. A. Dimou and V. Papadimitrakopoulou, “Non-small cell lung cancer beyond biomarkers: the evolving landscape of clinical trial design,” Journal of Personalized Medicine, vol. 4, no. 3, pp. 386–401, 2014. View at Publisher · View at Google Scholar
  3. F. Sampsonas, D. Ryan, D. McPhillips, and D. P. Breen, “Molecular testing and personalized treatment of lung cancer,” Current Molecular Pharmacology, vol. 7, no. 1, pp. 22–32, 2014. View at Google Scholar · View at Scopus
  4. W. S. Wu and Y. M. Chen, “Re-treatment with EGFR-TKIs in NSCLC patients who developed acquired resistance,” Journal of Personalized Medicine, vol. 4, no. 3, pp. 297–310, 2014. View at Publisher · View at Google Scholar
  5. Z. Wang, B. Wang, H. Guo, G. Shi, and X. Hong, “Clinicopathological significance and potential drug target of T-cadherin in NSCLC,” Drug Design, Development and Therapy, vol. 9, pp. 207–216, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. Z. Y. Du, M. H. Shi, C. H. Ji, and Y. Yu, “Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 4, pp. 1421–1425, 2015. View at Google Scholar
  7. T. Slavik, F. Asselah, N. Fakhruddin et al., “Diagnosis and predictive molecular analysis of non-small-cell lung cancer in the Africa-Middle East region: challenges and strategies for improvement,” Clinical Lung Cancer, vol. 15, no. 6, pp. 398–404, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Ulivi, A. Delmonte, E. Chiadini et al., “Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient selection?” International Journal of Molecular Sciences, vol. 16, no. 1, pp. 747–757, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. M. V. Iorio and C. M. Croce, “microRNA involvement in human cancer,” Carcinogenesis, vol. 33, no. 6, pp. 1126–1133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. I. Koturbash, F. J. Zemp, I. Pogribny, and O. Kovalchuk, “Small molecules with big effects: the role of the microRNAome in cancer and carcinogenesis,” Mutation Research—Genetic Toxicology and Environmental Mutagenesis, vol. 722, no. 2, pp. 94–105, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. J. O. Kim, S. Gazala, R. Razzak et al., “Non-small cell lung cancer detection using microRNA expression profiling of bronchoalveolar lavage fluid and sputum,” Anticancer Research, vol. 35, no. 4, pp. 1873–1880, 2015. View at Google Scholar
  12. S. Y. Lee, J. E. Choi, H. S. Jeon et al., “A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer,” Annals of Oncology, vol. 26, no. 6, pp. 1142–1148, 2015. View at Publisher · View at Google Scholar
  13. W. Gao, Y. Yu, H. Cao et al., “Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis,” Biomedicine and Pharmacotherapy, vol. 64, no. 6, pp. 399–408, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Markou, I. Sourvinou, P. A. Vorkas, G. M. Yousef, and E. Lianidou, “Clinical evaluation of microRNA expression profiling in non small cell lung cancer,” Lung Cancer, vol. 81, no. 3, pp. 388–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Yang, H. Shen, C. Qiu et al., “High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer,” European Journal of Cancer, vol. 49, no. 3, pp. 604–615, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. E. B. Buscaglia and Y. Li, “Apoptosis and the target genes of microRNA-21,” Chinese Journal of Cancer, vol. 30, no. 6, pp. 371–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T. Jacob, and T. Patel, “MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer,” Gastroenterology, vol. 133, no. 2, pp. 647–658, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. T.-S. Wong, X.-B. Liu, B. Y.-H. Wong, R. W.-M. Ng, A. P.-W. Yuen, and W. I. Wei, “Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue,” Clinical Cancer Research, vol. 14, no. 9, pp. 2588–2592, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. Z. Huang, D. Huang, S. Ni, Z. Peng, W. Sheng, and X. Du, “Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer,” International Journal of Cancer, vol. 127, no. 1, pp. 118–126, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-J. Liu, S.-Y. Kao, H.-F. Tu, M.-M. Tsai, K.-W. Chang, and S.-C. Lin, “Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer,” Oral Diseases, vol. 16, no. 4, pp. 360–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Yamamoto, N. Kosaka, M. Tanaka et al., “MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma,” Biomarkers, vol. 14, no. 7, pp. 529–538, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. G.-L. Liu, X. Liu, X.-B. Lv, X.-P. Wang, X.-S. Fang, and Y. Sang, “miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA),” International Journal of Clinical and Experimental Medicine, vol. 7, no. 8, pp. 1990–1999, 2014. View at Google Scholar · View at Scopus
  23. H.-F. Qin, L.-L. Qu, L.-L. Liu, S.-S. Wang, and H.-J. Gao, “Serum CEA level change and its significance before and after gefitinib therapy on patients with advanced non-small cell lung cancer,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 7, pp. 4205–4208, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Yang, H. Meng, Q. Peng et al., “Downregulation of microRNA-21 expression restrains non-small cell lung cancer cell proliferation and migration through upregulation of programmed cell death 4,” Cancer Gene Therapy, vol. 22, no. 1, pp. 23–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Qi, D.-Y. Yang, and J. Cao, “Increased micro-RNA 17, 21, and 192 gene expressions improve early diagnosis in non-small cell lung cancer,” Medical Oncology, vol. 31, article 195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Stenvold, T. Donnem, S. Andersen et al., “High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome,” BMC Clinical Pathology, vol. 14, no. 1, article 9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Li, W. Li, Q. Ouyang, S. Hu, and J. Tang, “Detection of lung cancer with blood microRNA-21 expression levels in Chinese population,” Oncology Letters, vol. 2, no. 5, pp. 991–994, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Ono, K. Yamada, F. Avolio et al., “Targeted knock-down of miR21 primary transcripts using snoMEN vectors induces apoptosis in human cancer cell lines,” PLOS ONE, vol. 10, no. 9, Article ID e0138668, 2015. View at Publisher · View at Google Scholar
  29. K. Wu, L. Li, and S. Li, “Circulating microRNA-21 as a biomarker for the detection of various carcinomas: an updated meta-analysis based on 36 studies,” Tumor Biology, vol. 36, no. 3, pp. 1973–1981, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. C. Cui, X. Sun, J. Zhang, D. Han, and J. Gu, “The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis,” Journal of Cancer Research and Therapeutics, vol. 10, no. 7, pp. C131–C134, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Szturmowicz, P. Rudziński, A. Kacprzak et al., “Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer,” Pneumonologia i Alergologia Polska, vol. 82, no. 5, pp. 422–429, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Jung, S. H. Kim, Y. J. Lee et al., “Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib,” Experimental and Therapeutic Medicine, vol. 2, no. 4, pp. 685–693, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. H. J. Yan, Y. Tan, and W. Gu, “Neuron specific enolase and prognosis of non-small cell lung cancer: a systematic review and meta-analysis,” Journal of BUON, vol. 19, no. 1, pp. 153–156, 2014. View at Google Scholar
  34. M. A. Alm El-Din, G. Farouk, H. Nagy, A. A. Elzaher, and G. H. Abo El-Magd, “Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer,” International Journal of Biological Markers, vol. 27, no. 2, pp. 139–146, 2012. View at Publisher · View at Google Scholar · View at Scopus